Medartis Holding AG
SIX:MED

Watchlist Manager
Medartis Holding AG Logo
Medartis Holding AG
SIX:MED
Watchlist
Price: 67.3 CHF 3.22% Market Closed
Market Cap: 915.3m CHF

Medartis Holding AG
Investor Relations

Medartis Holding AG operates as a medical device company. The company is headquartered in Basel, Basel-Stadt and currently employs 684 full-time employees. The company went IPO on 2018-03-23. The Group develops, manufactures and distributes to surgeons, hospitals and medical centers titanium screws, plates, surgical instruments and system solutions for internal fracture fixation. Medartis AG, the Company's wholly-owned subsidiary, has developed such technologies as TriLock for locking the screw into the plate, SpeedTip, a screw that does not require pre-drilling, and HexaDrive self-holding screw and screw-driver. The company has two product lines. The APTUS product line comprises upper and lower extremities products for hand, wrist, elbow, shoulder and foot fixation. The MODUS line combines products dedicated to cranio-maxillofacial (CMF) surgery. The Group's products are sold globally in more than 30 countries, including Germany and the United States, either directly through its sales subsidiaries, or through third-party distributors.

Show more
Loading
MED
Swiss Market Index

Earnings Calls

2023 Q2
Aug 15, 2023
Show Transcript
Previous
Next
Company Optimistic Despite H1 Margins Drop
2023 Q2
Aug 15, 2023

In the first half of the year, a series of mix effects triggered a gross margin decline by approximately 250 basis points. These effects included manufacturing sales dilution, distributor sales depressions, and inventory efficiency initiatives reducing production utilization. Nevertheless, the company sees these impacts diminishing in the second half. Operating expenses (OpEx) decreased around 7 percentage points year-on-year, indicating strong business leverage and confidence in meeting the full-year EBITDA margin guidance. Despite a CHF 50 million cash outflow and increased investments, the management expects H2 cash outflow to be significantly lower due to working capital improvements, non-recurrence of certain investments, and anticipated higher sales and gross margins. Consolidating the U.S. office to Warsaw improved the cost basis, with potential for expanding in various medical indications. The company confirms guidance for the full year, with internal sales growth between 15-18% and an EBITDA margin of 13-15%.

Show Full Analysis

Management

Dr. Thomas Straumann
Founder & Vice Chairman
No Bio Available
Mr. Matthias Schupp
CEO & Member of the Executive Management Board
No Bio Available
Dr. Dirk W. Kirsten Ph.D.
CFO & Member of the Executive Management Board
No Bio Available
Ms. Mareike Loch
VP of EMEA & Member of Executive Management Board
No Bio Available
Mr. Manuel Schaer
CTO & Member of the Executive Board
No Bio Available
Mr. Mario Della Casa
COO & Member of Management Board
No Bio Available
Ms. Inge Maes
Chief Human Resources Officer & Executive Management Board Member
No Bio Available
Ms. Anisha Wharton
Head of Regulatory Affairs
No Bio Available

Contacts

Address
BASEL-STADT
Basel
Hochbergerstrasse 60E
Contacts
+41616333434.0
www.medartis.com